Soft tissue sarcomas are rare and involve a well-integrated multimodality approach to optimize outcomes and decrease morbidity. It has been shown in the literature that sarcomas should be managed with interaction among experts in surgery, radiation and medical oncology, radiology and pathology extensively discuss each case. This, in turn, leads to improved clinical outcomes. In the proposed refresher session will present existing and new data on the multidisciplinary management of sarcomas pertaining to surgery, radiation therapy and systemic therapy.
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, participants should be able to do the following:
- Appreciate the importance of new and existing data in the management of adult sarcomas.
- Discuss the nuances in management of sarcomas as it pertains to histology, location and additional clinical aspects that impact treatment recommendations.
- Implement the knowledge gained to manage sarcoma cases across disciplines.
Meena Bedi, MD, is employed by the Medical College of Wisconsin and receives compensation from Varian.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 Certificate of AttendanceThis activity was designated for 0.50 AMA PRA Category 1 Credit™.